Disclosed herein are compositions and methods for use in therapeutic procedures. Use of a “fast-acting” botulinum toxin for cosmetic treatment and/or to prevent or reduce scarring. “Fast-acting” refers to a botulinum toxin that produces effects in the patient more rapidly than those produced by, for example, a botulinum neurotoxin type A. The “fast-acting” botulinum toxin, for example, type E.

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.

This invention provide novel compositions, methods and devices for sustained drug delivery. The compositions can include a fluid carrier; a plurality of first polymeric microparticles having a bioactive agent dispersed in the fluid carrier; and a plurality of second polymeric microparticles having a visualization agent dispersed in the fluid carrier with the first microparticles. Alternative compositions can include: a fluid carrier; and a plurality of polymeric microparticles having a bioactive agent encapsulated therein and a visualization agent on a surface of the polymeric microparticles, the plurality of polymeric microparticles being dispersed in the fluid carrier. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes at an amount of 1.0E-03 mL to 1.0E-16 mL per injection.

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.

Disclosed herein is a recombinant protein including botulinum toxin and cell penetrating peptides and cosmetic composition. The cell penetrating peptide according to the present disclosure may be actively used as a topical agent for various disease treatment, aesthetic, or cosmetic purposes, especially for a cosmetic composition, by securing better convenience as well as maximizing the intrinsic in vivo efficacy of the botulinum toxin through the cell penetrating recombinant proteins that combines the botulinum toxin and a cell penetrating peptide by making skin penetration and/or cell penetration for botulinum toxin more efficient.

Described herein is a novel application involving the use of therapeutic or cosmetic formulations of botulinum toxin involving an increase and enhancement of longevity in human subjects. The inventors are physicians who have used this agent for the past 30 years for many indications and has treated a large number of patients for periods of 20-30 years, many over the age of 60 at therapy initiation for medical and aesthetic conditions. A substantial number seemed to be surviving longer than untreated patients using US census statistics. Compared to social security survival curve established over the last decade, this patient group demonstrated substantial greater longevity than the national average. Because the first remarkable patients were a group exceeding or approaching 100 years of age, the phenomenon has been termed the “centurion effect.” The physiology of this effect most likely relates to the effect botulinum has on central nervous system, circadian function, sleep synchronization, mitigation of the deterioration of age related diurnal central nervous system functions, and metabolic alterations associated with the toxins effect on brainstem circadian centers.

The present invention relates to: a novel cell penetrating peptide; a cell penetrating botulinum toxin recombinant protein composition in which the cell penetrating peptide and the light chain of a botulinum toxin are fused; and a use thereof and, more specifically, to a composition enabling the transdermal delivery of a cell penetrating botulinum toxin recombinant protein and capable of being locally used for various treatments of the skin and cosmetic purposes. The cell penetrating peptide-botulinum toxin recombinant protein of the present invention can be transdermally delivered, thereby having the intrinsic effect of a botulinum toxin and simultaneously having greater convenience of use, and thus can be effectively applied as a local agonist for the treatment of various diseases and aesthetic and/or cosmetic purposes.

The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is about 1.5-2 times higher than that in the medium that is in current use. In addition, when botulinum toxin is produced by culturing the bacterium in the medium, infection with transmissible spongiform encephalopathy (TSE) or the like can be prevented by blocking introduction of animal-derived components.

The invention provides for methods for treating gastric cancer or colon cancer in a subject by administering a cholinergic antagonist, a Botulinum toxin, a NGF inhibitior, a TRK inhibitor, or performing a surgical denervation. The invention provides for inhibiting stem cells growth by administering a cholinergic antagonist, a Botulinum toxin, a NGF inhibitior, a TRK inhibitor, or performing a surgical denervation. The invention provides for stimulating regeneration of the colon or stomach by administering a cholinergic agonist.